Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 Memorial Sloan Kettering Cancer Center;
  • 2 O'Neal Comprehensive Cancer Center at UAB;
  • 3 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • 4 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • 5 Huntsman Cancer Institute at the University of Utah;
  • 6 Duke Cancer Institute;
  • 7 University of Wisconsin Carbone Cancer Center;
  • 8 Massachusetts General Hospital Cancer Center;
  • 9 Moffitt Cancer Center;
  • 10 Vanderbilt-Ingram Cancer Center;
  • 11 Stanford Cancer Institute;
  • 12 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • 13 The University of Tennessee Health Science Center;
  • 14 Mayo Clinic Cancer Center;
  • 15 Fox Chase Cancer Center;
  • 16 The University of Texas MD Anderson Cancer Center;
  • 17 Dana-Farber/Brigham and Women’s Cancer Center;
  • 18 Roswell Park Comprehensive Cancer Center;
  • 19 University of Colorado Cancer Center;
  • 20 City of Hope National Medical Center;
  • 21 UC San Diego Moores Cancer Center;
  • 22 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • 23 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • 24 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • 25 Abramson Cancer Center at the University of Pennsylvania;
  • 26 University of Michigan Rogel Cancer Center;
  • 27 UCSF Helen Diller Family Comprehensive Cancer Center;
  • 28 Fred & Pamela Buffett Cancer Center; and
  • 29 National Comprehensive Cancer Network
Restricted access

Treatment is complex for patients with head and neck (H&N) cancers with specific site of disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning for H&N cancers involves a multidisciplinary team of experts. This article describes supportive care recommendations in the NCCN Guidelines for Head and Neck Cancers, as well as the rationale supporting a new section on imaging recommendations for patients with H&N cancers. This article also describes updates to treatment recommendations for patients with very advanced H&N cancers and salivary gland tumors, specifically systemic therapy recommendations.

Individual Disclosures for the NCCN Head and Neck Cancers Panel

TU1

  • 1.

    Treatment of head and neck cancer. in.DeVita VT, Jr., Lawrence TS and Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2011.

    • Search Google Scholar
    • Export Citation
  • 2.

    DeVita V, Jr., Lawrence T, Rosenberg S. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, 9th Ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2011.

    • Search Google Scholar
    • Export Citation
  • 3.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:730.

  • 4.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:734.

  • 5.

    Chaturvedi AK, Engels EA, Pfeiffer RM, . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:42944301.

  • 6.

    Gillison ML, Broutian T, Pickard RK, . Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693703.

  • 7.

    Chaturvedi AK, Engels EA, Anderson WF, . Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612619.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Näsman A, Attner P, Hammarstedt L, . Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362366.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mehanna H, Beech T, Nicholson T, . Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747755.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Chua MLK, Wee JTS, Hui EP, . Nasopharyngeal carcinoma. Lancet 2016;387:10121024.

  • 11.

    Jha HC, Pei Y, Robertson ES. Epstein-Barr virus: diseases linked to infection and transformation [published online October 25, 2016]. Front Microbiol, doi:10.3389/finicb.2016.01602

    • Search Google Scholar
    • Export Citation
  • 12.

    Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004;5:423428.

  • 13.

    Ou SH, Zell JA, Ziogas A, . Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol 2007;18:2935.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Amin M, Edge S, Greene F, . AJCC Cancer Staging Manual, 8th Ed. New York: Springer;. 2017.

  • 15.

    Wuthrick EJ, Zhang Q, Machtay M, . Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 2015;33:156164.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    David JM, Ho AS, Luu M, . Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer. Cancer 2017;123:39333942.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Gourin CG, Stewart CM, Frick KD, . Association of hospital volume with laryngectomy outcomes in patients with larynx cancer. JAMA Otolaryngol Head Neck Surg 2019;145:6270.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Nocon CC, Ajmani GS, Bhayani MK. Association of facility volume with positive margin rate in the surgical treatment of head and neck cancer. JAMA Otolaryngol Head Neck Surg 2018;144:10901097.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Lee NCJ, Kelly JR, An Y, . Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer 2019;125:20182026.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Cohen EE, LaMonte SJ, Erb NL, . American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66:203239.

  • 21.

    Jabbour J, Milross C, Sundaresan P, . Education and support needs in patients with head and neck cancer: A multi-institutional survey. Cancer 2017;123:19491957.

  • 22.

    Chaukar DA, Walvekar RR, Das AK, . Quality of life in head and neck cancer survivors: a cross-sectional survey. Am J Otolaryngol 2009;30:176180.

  • 23.

    So WK, Chan RJ, Chan DN, . Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review. Eur J Cancer 2012;48:23912408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Smith BG, Hutcheson KA, Little LG, . Lymphedema outcomes in patients with head and neck cancer. Otolaryngol Head Neck Surg 2015;152:284291.

  • 25.

    Colasanto JM, Prasad P, Nash MA, . Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology (Williston Park) 2005;19:371379., discussion 380–382., 387.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Lin BM, Starmer HM, Gourin CG. The relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy. Laryngoscope 2012;122:15181525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Krebber AM, Leemans CR, de Bree R, . Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial. BMC Cancer 2012;12:173.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Verdonck-de Leeuw IM, de Bree R, Keizer AL, . Computerized prospective screening for high levels of emotional distress in head and neck cancer patients and referral rate to psychosocial care. Oral Oncol 2009;45:e129e133.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Andersen BL, DeRubeis RJ, Berman BS, . Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 2014;32:16051619.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:529.

  • 31.

    Schnoll RA, Zhang B, Rue M, . Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2003;21:355365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Gritz ER, Carr CR, Rapkin D, . Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1993;2:261270.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455468.

  • 34.

    Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593602.

  • 35.

    Piccirillo JF, Lacy PD, Basu A, . Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg 2002;128:11721179.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Chen AY, Matson LK, Roberts D, . The significance of comorbidity in advanced laryngeal cancer. Head Neck 2001;23:566572.

  • 37.

    Hall SF, Rochon PA, Streiner DL, . Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002;112:19881996.

  • 38.

    Rose BS, Jeong JH, Nath SK, . Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011;29:35033509.

  • 39.

    de Graeff A, de Leeuw JR, Ros WJ, . Pretreatment factors predicting quality of life after treatment for head and neck cancer. Head Neck 2000;22:398407.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Funk GF, Karnell LH, Whitehead S, . Free tissue transfer versus pedicled flap cost in head and neck cancer. Otolaryngol Head Neck Surg 2002;127:205212.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Farwell DG, Reilly DF, Weymuller EA, Jr., . Predictors of perioperative complications in head and neck patients. Arch Otolaryngol Head Neck Surg 2002;128:505511.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Charlson ME, Pompei P, Ales KL, . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373383.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974;27:387404.

  • 44.

    Piccirillo JF, Tierney RM, Costas I, . Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:24412447.

  • 45.

    Patrick D, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press;1993.

    • Search Google Scholar
    • Export Citation
  • 46.

    Yueh B. Measuring and Reporting Quality of Life in Head and Neck Cancer. McLean, Virginia. 2002.

  • 47.

    Rogers SN, Gwanne S, Lowe D, . The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck 2002;24:521529.

  • 48.

    Bjordal K, Hammerlid E, Ahlner-Elmqvist M, . Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999;17:10081019.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Cella D. Manual for the Functional Assessment of Cancer Therapy (FACT) Measurement System (version 4). Chicago, IL: Rush Medical Center; 1997.

    • Search Google Scholar
    • Export Citation
  • 50.

    List MA, D’Antonio LL, Cella DF, . The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale; a study of utility and validity. Cancer 1996;77:22942301.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Paleri V, Urbano TG, Mehanna H, . Management of neck metastases in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130(S2):S161S169.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Sun R, Tang X, Yang Y, . (18)FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis. Oral Oncol 2015;51:314320.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Kim SJ, Pak K, Kim K. Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients; A systematic review and meta-analysis. Am J Otolaryngol 2019;40:297305.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Kyzas PA, Evangelou E, Denaxa-Kyza D, . 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100:712720.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Yi X, Fan M, Liu Y, . 18 FDG PET and PET-CT for the detection of bone metastases in patients with head and neck cancer. A meta-analysis. J Med Imaging Radiat Oncol 2013;57:674679.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Rohde M, Nielsen AL, Johansen J, . Head-to-head comparison of chest X-ray/head and neck MRI, chest CT/head and neck MRI, and (18)F-FDG PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal cancer. J Nucl Med 2017;58:19191924.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Hosni A, Huang SH, Chiu K, . Predictors of early recurrence prior to planned postoperative radiation therapy for oral cavity squamous cell carcinoma and outcomes following salvage intensified radiation therapy. Int J Radiat Oncol Biol Phys 2019;103:363373.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Liauw SL, Mancuso AA, Amdur RJ, . Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol 2006;24:14211427.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Porceddu SV, Jarmolowski E, Hicks RJ, . Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005;27:175181.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Yao M, Smith RB, Hoffman HT, . Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009;74:914.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Lango MN, Myers JN, Garden AS. Controversies in surgical management of the node-positive neck after chemoradiation. Semin Radiat Oncol 2009;19:2428.

  • 62.

    Kutler DI, Patel SG, Shah JP. The role of neck dissection following definitive chemoradiation. Oncology (Williston Park) 2004;18:993998; discussion 999, 1003–1004, 1007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Cheung PK, Chin RY, Eslick GD. Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT: systematic review and meta-analysis. Otolaryngol Head Neck Surg 2016;154:421432.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Heineman TE, Kuan EC, St John MA. When should surveillance imaging be performed after treatment for head and neck cancer? Laryngoscope 2017;127:533534.

  • 66.

    Mehanna H, Wong WL, McConkey CC, . PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016;374:14441454.

  • 67.

    Mehanna H, McConkey CC, Rahman JK, . PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess 2017;21:1122.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Corry J, Peters L, Fisher R, . N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 2008;30:737742.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Lau H, Phan T, Mackinnon J, . Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2008;134:257261.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Ong SC, Schöder H, Lee NY, . Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49:532540.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Nayak JV, Walvekar RR, Andrade RS, . Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007;117:21292134.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Abgral R, Querellou S, Potard G, . Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:2429.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Porceddu SV, Pryor DI, Burmeister E, . Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33:16751682.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Ho AS, Tsao GJ, Chen FW, . Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer 2013;119:13491356.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Trosman SJ, Koyfman SA, Ward MC, . Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 2015;141:457462.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Sheikhbahaei S, Taghipour M, Ahmad R, . Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: a systematic review and meta-analysis. AJR Am J Roentgenol 2015;205:629639.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Dunsky KA, Wehrmann DJ, Osman MM, . PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope 2013;123:21612164.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Aberle DR, Adams AM, Berg CD, . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395409.

  • 79.

    Humphrey LL, Deffebach M, Pappas M, . Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 2013;159:411420.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Cousins N, MacAulay F, Lang H, . A systematic review of interventions for eating and drinking problems following treatment for head and neck cancer suggests a need to look beyond swallowing and trismus. Oral Oncol 2013;49:387400.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Locher JL, Bonner JA, Carroll WR, . Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicine. JPEN J Parenter Enteral Nutr 2011;35:365374.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Langius JA, van Dijk AM, Doornaert P, . More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. Nutr Cancer 2013;65:7683.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    August DA, Huhmann MB. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009;33:472500.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Garg S, Yoo J, Winquist E. Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review. Support Care Cancer 2010;18:667677.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Rabeneck L, McCullough LB, Wray NP. Ethically justified, clinically comprehensive guidelines for percutaneous endoscopic gastrostomy tube placement. Lancet 1997;349:496498.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Alshadwi A, Nadershah M, Carlson ER, . Nutritional considerations for head and neck cancer patients: a review of the literature. J Oral Maxillofac Surg 2013;71:18531860.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Raber-Durlacher JE, Brennan MT, Verdonck-de Leeuw IM, . Swallowing dysfunction in cancer patients. Support Care Cancer 2012;20:433443.

  • 88.

    Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer treatment: patients’ perspectives. Otolaryngol Head Neck Surg 2011;145:767771.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Tschiesner U. Preservation of organ function in head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012;11:Doc07.

  • 90.

    Bressan V, Bagnasco A, Aleo G, . The life experience of nutrition impact symptoms during treatment for head and neck cancer patients: a systematic review and meta-synthesis. Support Care Cancer 2017;25:16991712.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Roe JW, Carding PN, Rhys-Evans PH, . Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey. Oral Oncol 2012;48:343348.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Russi EG, Corvò R, Merlotti A, . Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treat Rev 2012;38:10331049.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Cnossen IC, de Bree R, Rinkel RN, . Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice. Support Care Cancer 2012;20:29252931.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Epstein JB, Thariat J, Bensadoun RJ, . Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012;62:400422.

  • 95.

    Vera-Llonch M, Oster G, Hagiwara M, . Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 2006;106:329336.

  • 96.

    Elting LS, Cooksley CD, Chambers MS, . Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007;68:11101120.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Trotti A, Bellm LA, Epstein JB, . Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Bar Ad V, Weinstein G, Dutta PR, . Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer 2010;116:42064213.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 99.

    Sroussi HY, Epstein JB, Bensadoun RJ, . Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med 2017;6:29182931.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Al-Ansari S, Zecha JA, Barasch A, . Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2015;2:202211.

  • 101.

    Lalla RV, Bowen J, Barasch A, . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014;120:14531461.

  • 102.

    Sio TT, Le-Rademacher JG, Leenstra JL, . Effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo on radiotherapy-related oral mucositis pain: the Alliance A221304 randomized clinical trial. JAMA 2019;321:14811490.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Bar Ad V, Weinstein G, Dutta PR, . Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. Head Neck 2010;32:173177.

    • Search Google Scholar
    • Export Citation
  • 104.

    Hermann GM, Iovoli AJ, Platek AJ, . A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer. Cancer 2020;126:14801491.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Koyfman SA, Adelstein DJ. Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review. Int J Radiat Oncol Biol Phys 2012;84:581589.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Walker MP, Wichman B, Cheng AL, . Impact of radiotherapy dose on dentition breakdown in head and neck cancer patients. Pract Radiat Oncol 2011;1:142148.

  • 107.

    Jensen SB, Pedersen AM, Vissink A, . A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010;18:10391060.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Deng J, Jackson L, Epstein JB, . Dental demineralization and caries in patients with head and neck cancer. Oral Oncol 2015;51:824831.

  • 109.

    Duarte VM, Liu YF, Rafizadeh S, . Comparison of dental health of patients with head and neck cancer receiving IMRT vs conventional radiation. Otolaryngol Head Neck Surg 2014;150:8186.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Murdoch-Kinch CA, Kim HM, Vineberg KA, . Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:373382.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Little M, Schipper M, Feng FY, . Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 2012;83:10071014.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Chao KS. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002; 12(1, Suppl 1)2025.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Murdoch-Kinch CA, Zwetchkenbaum S. Dental management of the head and neck cancer patient treated with radiation therapy. J Mich Dent Assoc 2011;93:2837.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Studer G, Glanzmann C, Studer SP, . Risk-adapted dental care prior to intensity-modulated radiotherapy (IMRT). Schweiz Monatsschr Zahnmed 2011;121:216229.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Ben-David MA, Diamante M, Radawski JD, . Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 2007;68:396402.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Thariat J, Ramus L, Darcourt V, . Compliance with fluoride custom trays in irradiated head and neck cancer patients. Support Care Cancer 2012;20:18111814.

  • 117.

    Chang DT, Sandow PR, Morris CG, . Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Head Neck 2007;29:528536.

  • 118.

    Gomez DR, Estilo CL, Wolden SL, . Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;81:e207e213.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Lee IJ, Koom WS, Lee CG, . Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys 2009;75:10841091.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    O’Dell K, Sinha U. Osteoradionecrosis. Oral Maxillofac Surg Clin North Am 2011;23:455464.

  • 121.

    Gevorgyan A, Wong K, Poon I, . Osteoradionecrosis of the mandible: a case series at a single institution. J Otolaryngol Head Neck Surg 2013;42:46.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 122.

    Jacobson AS, Buchbinder D, Hu K, . Paradigm shifts in the management of osteoradionecrosis of the mandible. Oral Oncol 2010;46:795801.

  • 123.

    Oh HK, Chambers MS, Martin JW, . Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg 2009;67:13781386.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Sohn HO, Park EY, Jung YS, . Effects of professional oral hygiene care in patients with head-and-neck cancer during radiotherapy: A randomized clinical trial. Indian J Dent Res 2018;29:700704.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Schiødt M, Hermund NU. Management of oral disease prior to radiation therapy. Support Care Cancer 2002;10:4043.

  • 126.

    Rhodus NL, Bereuter J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren’s syndrome. J Otolaryngol 2000;29:2834.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Singh ML, Papas AS. Long-term clinical observation of dental caries in salivary hypofunction patients using a supersaturated calcium-phosphate remineralizing rinse. J Clin Dent 2009;20:8792.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Epstein JB, Schubert MM. Synergistic effect of sialagogues in management of xerostomia after radiation therapy. Oral Surg Oral Med Oral Pathol 1987;64:179182.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Gorsky M, Epstein JB, Parry J, . The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:190195.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Johnson JT, Ferretti GA, Nethery WJ, . Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390395.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Dholam KP, Somani PP, Prabhu SD, . Effectiveness of fluoride varnish application as cariostatic and desensitizing agent in irradiated head and neck cancer patients [published online June 13, 2013]. Int J Dent 2013;2013:824982.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 132.

    Epstein JB, van der Meij EH, Lunn R, . Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:268275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Horiot JC, Schraub S, Bone MC, . Dental preservation in patients irradiated for head and neck tumours: A 10-year experience with topical fluoride and a randomized trial between two fluoridation methods. Radiother Oncol 1983;1:7782.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 134.

    Fleming TJ. Use of topical fluoride by patients receiving cancer therapy. Curr Probl Cancer 1983;7:3741.

  • 135.

    Beumer J III, Harrison R, Sanders B, . Postradiation dental extractions: a review of the literature and a report of 72 episodes. Head Neck Surg 1983;6:581586.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 136.

    Shulman DH, Shipman B, Willis FB. Treating trismus with dynamic splinting: a case report. J Oral Sci 2009;51:141144.

  • 137.

    Teguh DN, Levendag PC, Voet P, . Trismus in patients with oropharyngeal cancer: relationship with dose in structures of mastication apparatus. Head Neck 2008;30:622630.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Brunello DL, Mandikos MN. The use of a dynamic opening device in the treatment of radiation induced trismus. Aust Prosthodont J 1995;9:4548.

  • 139.

    Epstein JB, Emerton S, Le ND, . A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 1999;35:132137.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Papas A, Russell D, Singh M, . Caries clinical trial of a remineralising toothpaste in radiation patients. Gerodontology 2008;25:7688.

  • 141.

    Adelstein DJ, Li Y, Adams GL, . An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:9298.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Lo TC, Wiley AL, Jr., Ansfield FJ, . Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol 1976;126:229235.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Sanchíz F, Millá A, Torner J, . Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:13471350.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Browman GP, Cripps C, Hodson DI, . Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:26482653.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Smid L, Lesnicar H, Zakotnik B, . Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report. Int J Radiat Oncol Biol Phys 1995;32:769775.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Bachaud JM, Cohen-Jonathan E, Alzieu C, . Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:9991004.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Merlano M, Benasso M, Corvò R, . Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583589.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Brizel DM, Albers ME, Fisher SR, . Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:17981804.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Wendt TG, Grabenbauer GG, Rödel CM, . Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:13181324.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Jeremic B, Shibamoto Y, Milicic B, . Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:14581464.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:8391.

  • 152.

    El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838847.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Pignon JP, Bourhis J, Domenge C, . Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949955.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 154.

    Bourhis J, Amand C, Pignon J-P. Update of MACH-NC (meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemoradiotherapy [abstract]. J Clin Oncol 2004;22(Suppl 14):Abstract 5505.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 155.

    Pignon JP, le Maître A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69(Suppl)S112S114.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Sher DJ, Adelstein DJ, Bajaj GK, . Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2017;7:246253.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Rubin Grandis J, Melhem MF, Gooding WE, . Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824832.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 158.

    Zhu X, Zhang F, Zhang W, . Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol 2013;108:387397.

  • 159.

    Bonner JA, Harari PM, Giralt J, . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567578.

  • 160.

    Bonner JA, Harari PM, Giralt J, . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:2128.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Ang KK, Zhang Q, Rosenthal DI, . Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:29402950.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Tao Y, Auperin A, Sire C, . Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial [published online June 7, 2018]. J Clin Oncol, doi: 10.1200/JCO.2017.76.2518

    • Search Google Scholar
    • Export Citation
  • 163.

    Gillison ML, Trotti AM, Harris J, . Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019;393:4050.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Mehanna H, Robinson M, Hartley A, . Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393:5160.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Forastiere AA, Zhang Q, Weber RS, . Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845852.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    Bourhis J, Sire C, Graff P, . Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13:145153.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 167.

    Cohen EE, Karrison TG, Kocherginsky M, . Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014;32:27352743.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Haddad R, O’Neill A, Rabinowits G, . Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013;14:257264.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 169.

    Magrini SM, Buglione M, Corvò R, . Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol 2016;34:427435.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 170.

    Garden AS, Harris J, Vokes EE, . Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:28562864.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    Beckmann GK, Hoppe F, Pfreundner L, . Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005;27:3643.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Medina JA, Rueda A, de Pasos AS, . A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 2006;79:3438.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    Suntharalingam M, Haas ML, Conley BA, . The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000;47:4956.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Taylor SG IV, Murthy AK, Vannetzel JM, . Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994;12:385395.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Sun XS, Michel C, Babin E, . Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. Future Oncol 2018;14:877889.

  • 176.

    Bonomo P, Greto D, Desideri I, . Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal? Oral Oncol 2019;93:17.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Bates JE, De Leo AN, Morris CG, . Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single-institution outcomes. Head Neck 2019;41:23092314.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Fury MG, Pfister DG. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 2011;9:681689.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Molin Y, Fayette J. Current chemotherapies for recurrent/metastatic head and neck cancer. Anticancer Drugs 2011;22:621625.

  • 180.

    Hoffmann TK. Systemic therapy strategies for head-neck carcinomas: Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012;11:Doc03.

  • 181.

    Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012;13:3546.

  • 182.

    Gibson MK, Li Y, Murphy B, . Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:35623567.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Forastiere AA, Metch B, Schuller DE, . Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:12451251.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 184.

    Jacobs C, Lyman G, Velez-García E, . A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257263.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 1994;21:311319.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Clavel M, Vermorken JB, Cognetti F, . Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521526.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 187.

    Vermorken JB, Mesia R, Rivera F, . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:11161127.

  • 188.

    Burtness B, Harrington KJ, Greil R, . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:19151928.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    Cohen EEW, Soulières D, Le Tourneau C, .KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156167.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 190.

    Ferris RL, Blumenschein G, Jr., Fayette J, . Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:18561867.

  • 191.

    Samlowski WE, Moon J, Kuebler JP, . Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182188.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 192.

    Burtness B, Goldwasser MA, Flood W, . Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:86468654.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    Bossi P, Miceli R, Locati LD, . A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2017;28:28202826.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 194.

    Guigay J, Fayette J, Dillies A-F, . Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03 [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract 5505.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 195.

    Herbst RS, Arquette M, Shin DM, . Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:55785587.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 196.

    Tahara M, Kiyota N, Yokota T, . Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol 2018;29:10041009.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 197.

    Grau JJ, Caballero M, Verger E, . Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009;129:12941299.

  • 198.

    Guardiola E, Peyrade F, Chaigneau L, . Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:20712076.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Catimel G, Verweij J, Mattijssen V, .EORTC Early Clinical Trials Group. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533537.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 200.

    Stewart JS, Cohen EE, Licitra L, . Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. [corrected] J Clin Oncol 2009;27:1864–1871; erratum in: J Clin Oncol 2009;27:3410.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 201.

    Haigentz M, Jr., Hartl DM, Silver CE, . Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. Oral Oncol 2012;48:787793.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Martinez-Trufero J, Isla D, Adansa JC, . Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102:16871691.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 203.

    Vermorken JB, Trigo J, Hitt R, . Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:21712177.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 204.

    Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:26442652.

  • 205.

    Forastiere AA, Shank D, Neuberg D, . Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:22702274.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 206.

    Seiwert TY, Burtness B, Mehra R, . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17:956965.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    Chow LQM, Haddad R, Gupta S, . Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34:38383845.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Mehra R, Seiwert TY, Gupta S, . Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 2018;119:153159.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 209.

    Bauml J, Seiwert TY, Pfister DG, . Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 2017;35:15421549.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Machiels JP, Haddad RI, Fayette J, . Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015;16:583594.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 211.

    Clement PM, Gauler T, Machiels JP, . Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol 2016;27:15851593.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 212.

    Seiwert TY, Fayette J, Cupissol D, . A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014;25:18131820.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 213.

    Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986;8:177184.

  • 214.

    Bron LP, Traynor SJ, McNeil EB, . Primary and metastatic cancer of the parotid: comparison of clinical behavior in 232 cases. Laryngoscope 2003;113:10701075.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 215.

    Nagliati M, Bolner A, Vanoni V, . Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori 2009;95:442448.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 216.

    Garden AS, Weber RS, Morrison WH, . The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995;32:619626.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 217.

    Bell RB, Dierks EJ, Homer L, . Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005;63:917928.

  • 218.

    Copelli C, Bianchi B, Ferrari S, . Malignant tumors of intraoral minor salivary glands. Oral Oncol 2008;44:658663.

  • 219.

    Vander Poorten V, Bradley PJ, Takes RP, . Diagnosis and management of parotid carcinoma with a special focus on recent advances in molecular biology. Head Neck 2012;34:429440.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 220.

    Timoshchuk MA, Dekker P, Hippe DS, . The efficacy of neutron radiation therapy in treating salivary gland malignancies. Oral Oncol 2019;88:5157.

  • 221.

    Laramore GE, Krall JM, Griffin TW, . Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Int J Radiat Oncol Biol Phys 1993;27:235240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 222.

    Stannard C, Vernimmen F, Carrara H, . Malignant salivary gland tumours: can fast neutron therapy results point the way to carbon ion therapy? Radiother Oncol 2013;109:262268.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 223.

    Cederblad L, Johansson S, Enblad G, . Cancer of the parotid gland; long-term follow-up. A single centre experience on recurrence and survival. Acta Oncol 2009;48:549555.

    • Crossref
    • PubMed